Last reviewed · How we verify
Open-labelAdalimumabRescue
Adalimumab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha to reduce inflammation and immune-mediated disease activity.
Adalimumab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha to reduce inflammation and immune-mediated disease activity. Used for Rescue therapy in inflammatory bowel disease (Crohn's disease or ulcerative colitis) with inadequate response to standard therapy, Rescue therapy in rheumatoid arthritis with inadequate response to conventional DMARDs.
At a glance
| Generic name | Open-labelAdalimumabRescue |
|---|---|
| Also known as | ABT-D2E7, adalimumab, Humira |
| Sponsor | Abbott |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Adalimumab is a fully human monoclonal antibody that binds to and neutralizes TNF-alpha, a key pro-inflammatory cytokine. By blocking TNF-alpha signaling, it suppresses the inflammatory cascade and reduces immune cell activation. This mechanism is used as a rescue therapy in patients who have inadequate response to standard treatments.
Approved indications
- Rescue therapy in inflammatory bowel disease (Crohn's disease or ulcerative colitis) with inadequate response to standard therapy
- Rescue therapy in rheumatoid arthritis with inadequate response to conventional DMARDs
Common side effects
- Injection site reactions
- Upper respiratory tract infections
- Headache
- Nausea
- Serious infections
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Open-labelAdalimumabRescue CI brief — competitive landscape report
- Open-labelAdalimumabRescue updates RSS · CI watch RSS
- Abbott portfolio CI